Title III – Expansion of Productive Capacity and Supply

Investment Snapshot showing $128,782,696 total funding across MCM Supply Chain and Essential Medicines programs

The U.S. Department of Health and Human Services’ (HHS) Defense Production Act (DPA) Title III Program strengthens national defense by improving the resiliency, diversity, and security of supply chains for critical health resources needed to respond to public health emergencies.

Programmatic Objectives

Expand domestic manufacturing capabilities: Strengthen U.S. production of critical health resources.
Reduce supply chain vulnerabilities: Mitigate risks from global disruptions.
Promote innovation: Accelerate development of new technologies.
Ensure affordability and accessibility: Support equitable access to essential resources.

Executive Orders Supported

Essential Medicines Portfolio

Antheia, Inc.

Oripavine and Thebaine

KSM/API and FDF

Product:Oripavine and Thebaine

Product Category:KSM/API and FDF

Location:Menlo Park, CA (R&D) and Lafayette, IN (Mfg.)

Description:Modernize fermentation capacities to leverage bioengineering and computational biology to produce one (1) key starting material used to produce all priority essential reversal agents.

Unique Impact: Using Bio Synthetic manufacturing to end our drug shortages and reduce reliance on Petro Chemical drug manufacturing

Base Award Amount:$0

Projected DMF Filing Date:December 2026.

API Innovation Center (APIIC)

Albuterol, Metoprolol Succinate, Lorazepam, Propofol

KSM/API and FDF

Product:Albuterol, Metoprolol Succinate, Lorazepam, Propofol

Product Category:KSM/API and FDF

Location:St. Louis, MO

Description:Modernize manufacturing capacities at each of the non-profit coalition members (MilliporeSigma, University of Missouri – St. Louis, and Mallinckrodt Pharmaceuticals) via implementation of novel manufacturing processes and technologies to provide end-to-end domestic supply chains for all key starting materials and active pharmaceutical ingredients used to produce three (3) priority essential medicines

Unique Impact: Use of advanced manufacturing technologies using all domestic inputs

Base Award Amount:$0

Projected DMF Filing Date:December 2026.

Manus Bio, Inc.

Shikimic Acid

KSM/API and FDF

Product:Shikimic Acid

Product Category:KSM/API and FDF

Location: Augusta, GA

Description:Domestic production of Shikimic Acid, a critical component of Oseltamivir, a key starting material in Tamiflu. This award aims to decrease Tamiflu shortages in the U.S.

Unique Impact: Use of advanced manufacturing, including continuous flow chemistry

Base Award Amount:$0

Year Awarded: --

Medical Sterilization Portfolio

Meissner Corporation

Medical Sterilization

Product:Medical Sterilization

Product Category:Medical Sterilization

Description:Greenfield construction for X-ray sterilization facility (70,000 sq ft). Ensures sterilization capacity for U.S. Government emergency response

Steri-Tek

X-Ray and E-Beam Sterilization

Medical Sterilization

Product:X-Ray and E-Beam Sterilization

Product Category:Medical Sterilization

Description:Expand terminal sterilization facility to 3.5M cubic feet output per year to ensure sterilization capacity for public health emergencies.

Sterigenics

:X-Ray Sterilization

Medical Sterilization

Product::X-Ray Sterilization

Product Category:Medical Sterilization

Location:Haw River, NC

Description:Construct greenfield X-ray sterilization facility (3.5M cubic feet capacity) to ensure sterilization capacity for public health emergencies.